Waltham, Mass.— BostonGene, a leader in AI-powered molecular and immune profiling, has appointed Dr. Ferran Prat as its new Chief Commercial Officer (CCO). Dr. Prat will be responsible for leading the company’s commercial operations, including sales, marketing, and business development, as BostonGene continues to expand its role in transforming drug development and personalized medicine.
Dr. Prat brings a wealth of experience from the healthcare, pharmaceutical, and biotechnology sectors. Most recently, he served as Senior Vice President of Research Administration and Industry Relations at The University of Texas MD Anderson Cancer Center. There, he played a pivotal role in fostering strategic collaborations with the biopharma industry, accelerating the translation of scientific breakthroughs into clinical therapies.
“We are excited to welcome Ferran to BostonGene,” said Andrew Feinberg, President and CEO of BostonGene. “He brings a powerful combination of scientific knowledge, business strategy, and legal expertise. His ability to forge impactful industry partnerships will be vital as we grow our presence and continue leveraging AI to revolutionize healthcare.”
Dr. Prat praised BostonGene’s mission and technology, emphasizing the company’s unique position in the growing field of personalized medicine. “BostonGene is redefining what is possible at the intersection of science, data and patient care,” he said. “Its multimodal, multiscale AI-driven platform delivers crucial insights that accelerate therapeutic development and improve patient outcomes. I’m thrilled to help lead the next phase of growth.”
Before joining MD Anderson, Dr. Prat held leadership roles at Alere Inc., now part of Abbott Laboratories, and worked as a management consultant at McKinsey & Company. He holds a PhD in Organic Chemistry from UCLA and a JD from the University of San Diego School of Law.
With Dr. Prat at the helm of its commercial efforts, BostonGene is poised to deepen its industry partnerships and further its impact on advancing personalized therapies and precision medicine.
